New Blood Test Option for Early Detection of Colon Cancer Receives FDA Approval

The United States Food and Drug Administration (FDA) has approved a new screening procedure for the early detection of colon cancer that requires only a blood sample. This new testing method could increase the acceptance of colon cancer screenings, as it is less invasive compared to a colonoscopy or stool test. The blood test, named "Shield" and developed by Guardant Health in Palo Alto, California, can detect early-stage cancer, which is generally curable. However, a significant drawback of the test is its limited ability to detect precancerous growths, the removal of which could prevent cancer. Shield will be available starting next week and is aimed at individuals aged 45 and older with an average risk of colon cancer. The pricing of the test will be announced by Guardant at a later date, according to company spokesperson Matt Burns. Despite the limitations, it is hoped that the easy accessibility of this blood test will encourage more people to undergo regular screenings for colon cancer. In 2023, around 53,000 deaths from colon cancer are expected in the USA, making it the second leading cause of cancer-related deaths in the country. Regular early detection could prevent up to 73 percent of these deaths. Although current guidelines recommend regular screenings starting at age 45, between 25 and 50 percent of individuals who should undergo screenings are not regularly tested. There are high hopes for the new test, which can collect blood samples during a routine check-up or at a commercial laboratory.